ArticleiScience2025
Multi-trait association analysis reveals shared genetic architecture between lung cancer and cardiometabolic diseases.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer (LC) frequently coexists with cardiometabolic diseases (CMDs), complicating clinical management, but their shared genetic architecture remains largely unknown. Here, we analyzed genome-wide association study (GWAS) statistics for LC and 36 cardiometabolic traits and diseases (CMTs) to determine genetic correlations and shared biological pathways. We further explored underlying mechanisms through the analysis of bulk and single-cell RNA sequencing data and identified potential therapeutic candidates using drug-gene interaction databases. Significant genetic associations were revealed between LC and 16 CMTs, including subarachnoid hemorrhage, peripheral arterial disease, heart failure, and physiological traits (Padj <0.05). The shared genes were identified as enriched in lipid and cholesterol metabolism. Notably, monocyte-derived macrophages (mo-Macs) in lung adenocarcinoma exhibited M2-like polarization under high cholesterol metabolism and rosuvastatin and lovastatin were identified as potential drugs for LC-CMD comorbidities. Our findings demonstrate a role for cholesterol metabolism in LC-CMD comorbidities, offering insights into the underlying mechanisms and potential therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.